Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.
about
Rituximab for treating inhibitors in people with inherited severe hemophiliaBypassing agent prophylaxis in people with hemophilia A or B with inhibitorsRituximab for treating inhibitors in children with hemophiliaAlloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicitySwitching treatments in haemophilia: is there a risk of inhibitor development?Present and future challanges in the treatment of haemophilia: a clinician's perspectiveFVIII inhibitors: pathogenesis and avoidanceDifferent impact of factor VIII products on inhibitor development?Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.SIPPET: methodology, analysis and generalizability.The current state of adverse event reporting in hemophilia.The safety of pharmacologic options for the treatment of persons with hemophilia.A new recombinant factor VIII: from genetics to clinical use.Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families--15 new mutations.Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.Current and evolving features in the clinical management of haemophiliaInhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practicePrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyFactor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics.FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody.New treatments in hemophilia: insights for the clinician.Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivoHigh rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance.Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.Plasma-derived medicinal products self-sufficiency from national plasma: to what extent?Key issues in inhibitor management in patients with haemophilia.Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment.Factor VIII inhibitors: a 50-year perspective.Factor VIII safety: plasma-derived versus recombinant products.Pharmacotherapy of haemophilia A.Joint protection in haemophilia.Past, present and future of hemophilia: a narrative review.The modern treatment of haemophilia: a narrative reviewInhibitors: our greatest challenge. Can we minimize the incidence?Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors.
P2860
Q24186623-2C173FD5-924A-4796-A1AD-13D6E37DD880Q24187021-61D9124E-87EF-4EC3-BC64-0B6F824B7894Q24197700-2E522623-5ED9-44DA-98D2-512C0900FC25Q26866323-F6DDD8DE-FEA6-4825-AA30-E24269EC8AD8Q27001016-506D4E2B-1EC4-413E-B74E-4C197987C03FQ27026137-0541A04F-EE5F-4492-8389-8DF859E1251EQ27027224-F64B96F5-F385-4AD5-B797-B13DA0C77611Q28075679-82595EF5-CA87-40AA-B684-A3A80059F301Q30234910-69B31CCE-3D2F-4456-97F8-82D524AD6223Q30235225-45604513-A38C-4C12-92BB-05F6298C35F3Q30239952-0791D94E-3024-42BE-9E23-1220AB210C36Q30249200-59E68EAC-1D6A-4F11-9004-88FB643F874CQ30370282-10DA550C-C406-4A45-86F9-5908FB73F733Q30403462-F33BB778-A002-4031-B12F-E99ADC354AE4Q30958570-7938AEC9-470A-4C12-A680-A796D9116146Q33708976-4507C598-C05C-4AB3-8FC7-E7D41BA376B9Q34157402-CE4356B5-FF29-44D3-8E6C-0942954588BFQ34416394-709EB61C-F0C8-4B08-A798-F76599C6C84BQ34580100-924787B1-7718-4B9C-AC9A-1B15AD1804F3Q34784564-F5DD2574-2E2B-4E99-99A1-E9FA471F5192Q35209354-9D153826-7332-44E0-B2BB-629ECF355258Q35565320-B4BE8A6C-7251-40DB-A1E5-30B24B7F26B3Q36236913-5DC7D27E-0C26-475E-8710-194F8B3D208AQ36243815-52588E30-EE7D-4DF9-A5F2-C47FEB7CFD86Q36310238-F217629E-30B5-4527-8739-CEAE049E4CBCQ36612681-5A5A91D4-4493-40AD-8BC9-36AE99AEAD3EQ36897565-450A89E4-91EF-4FE0-94C2-ABCB83D33880Q37153668-BC7636B6-58A9-42F9-BF78-EA50C2F277B2Q37253340-71E62F35-5DB3-41BC-91D7-F14755048D45Q37370365-3AC58AC7-3323-4C67-8EDA-709FDFD91D34Q37602415-65B4A3D9-FD5D-4B88-BADB-185620457536Q37818493-0F2DECF0-14D8-467B-93BD-C79532C3C896Q37876956-89FF7E88-1744-44FF-A8EE-389E74FA1CD2Q37882787-1F325833-B6FB-4EC6-9557-FD5483D5D89DQ37891089-E9A757A8-DD78-44F2-9F9D-FC3F2BA3E96DQ37912258-204B4C4B-EDFA-4256-BA72-F31F20DCBC4AQ38007018-204400DB-31BB-413C-99B2-E1C5039A513AQ38025882-55C3F7EA-EE94-4A41-AA7F-072ED46DA073Q38070810-A2B3349B-DBAF-44C8-B995-7EE3BDE8EADDQ38080144-B467838A-29CB-44BA-B0B9-11C36C795F73
P2860
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rate of inhibitor development ...... entrates: a systematic review.
@en
Rate of inhibitor development ...... entrates: a systematic review.
@nl
type
label
Rate of inhibitor development ...... entrates: a systematic review.
@en
Rate of inhibitor development ...... entrates: a systematic review.
@nl
prefLabel
Rate of inhibitor development ...... entrates: a systematic review.
@en
Rate of inhibitor development ...... entrates: a systematic review.
@nl
P2093
P2860
P50
P921
P1476
Rate of inhibitor development ...... entrates: a systematic review.
@en
P2093
A Gringeri
C Bidlingmaier
C E Ettingshausen
E Marchesini
E Santagostino
L R Brandao
N Goldenberg
P2860
P304
P356
10.1111/J.1538-7836.2010.03823.X
P577
2010-03-17T00:00:00Z